Drug glossary Drug

JAB-3312

A drug being studied in colorectal cancer trials. It appears in 2 clinical trials.

Oral KRAS G12C
See its trials
United States Investigational
European Union Investigational
Spain Not available

What it is

JAB-3312 is a targeted therapy designed for treating advanced solid tumors, including colorectal cancer, in patients harboring KRAS G12C mutations. This compound represents a precision medicine approach that specifically addresses one of the most common oncogenic mutations found in colorectal cancer. JAB-3312 has shown particular promise when used in combination with JAB-21822 for patients with KRAS G12C-mutated tumors.

How it works

JAB-3312 functions as a KRAS G12C inhibitor that directly targets the mutated KRAS protein at the G12C position. This mutation results in constitutively active KRAS signaling that drives tumor growth and proliferation. By selectively binding to and inhibiting the KRAS G12C mutant protein, JAB-3312 disrupts downstream oncogenic signaling pathways critical for cancer cell survival.

Molecular targets

KRAS G12C

Common side effects

FatigueNauseaDiarrheaDecreased appetiteRashElevated liver enzymesAnemiaThrombocytopenia

Not all are listed, and everyone experiences them differently. If you notice any, tell your care team.

Guides that may help

Written for patients and families, in plain language.

KRAS mutation: what it means for your treatmentAlmost half of colorectal cancers carry a mutation in the KRAS gene. Today the most important consequence is that anti-EGFR…Eating during chemotherapy: what the evidence supports and what it does notThere is no "anti-cancer diet" that improves the outcome of chemotherapy. What is proven is that losing weight and muscle during…Cancer-related fatigue: what actually helpsCancer-related fatigue is the most common symptom during and after treatment, and it is not fixed by sleeping more. Before…
See all guides →